General MedicationsORALStandard
ARAKODA
TAFENOQUINE SUCCINATE
Standard Dose
EQ 100MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview ARAKODA is listed in Drugs@FDA under application 210607 (NDA).
Review priority: N/A Marketing status: Prescription Active ingredient TAFENOQUINE SUCCINATE Form and strength TABLET;ORAL - EQ 100MG BASE Sponsor 60 DEGREES PHARMS Submission history Latest submission status date: 2022-02-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview ARAKODA is listed in Drugs@FDA under application 210607 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient TAFENOQUINE SUCCINATE Form and strength TABLET;ORAL - EQ 100MG BASE Sponsor 60 DEGREES PHARMS Submission history Latest submission status date: 2022-02-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.